Holen Sie sich die Stockscreener-App
100.48
1.00%
-1.02
Handel nachbörslich:
100.05
-0.43
-0.43%
Incyte Corp Aktie (INCY) Neueste Nachrichten
Insider Selling: Incyte (NASDAQ:INCY) EVP Sells 20,105 Shares of Stock - MarketBeat
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)December 3, 2025 - BioSpace
Global Vitiligo Foundation Applauds Partnership Between Incyte and Winnie Harlow to Elevate Awareness and Understanding of Vitiligo - Yahoo Finance
Myeloproliferative Disorder Treatment Market Size Report 2032 - openPR.com
Mackenzie Financial Corp Has $24.67 Million Stock Position in Incyte Corporation $INCY - MarketBeat
Incyte and Winnie Harlow Join Forces to Share Her Personal Vitiligo Story and Spark Conversation and Understanding - Business Wire
Incyte Appoints Richard Hoffman as Executive Vice President and General Counsel - BioSpace
Incyte (INCY): Evaluating Valuation Following Recent Share Price Momentum - Yahoo Finance
Incyte appoints Richard Hoffman as executive VP and general counsel By Investing.com - Investing.com Nigeria
CACS Drug Market Accelerates at 3.9% CAGR to 2033, Reaching USD - openPR.com
Incyte Sets December Investor Lineup as Pipeline Progress Draws Market Attention - MyChesCo
Incyte (INCY) Up 17.2% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Incyte: This Profitable Biotech Trades Like A Melting Iceberg (NASDAQ:INCY) - Seeking Alpha
Incyte: Riding Jakafi, Bracing For Generic Headwinds (NASDAQ:INCY) - Seeking Alpha
Incyte’s principal accounting officer Tray Thomas sells $79k in stock - Investing.com
Incyte receives the first letter confirming compliance following the FDA’s Untitled Letter spree - Medical Marketing and Media
Opzelura From Incyte Corp. - Pharmacy Times
Incyte Outpaces Expectations And Raises Its Revenue Forecast - Finimize
Incyte Corp. Stock Climbs 4.1%, Outperforms Peers - 富途牛牛
Integra LifeSciences, Evolent Health, Incyte, iRhythm, and Clover Health Stocks Trade Up, What You Need To Know - Yahoo Finance
Incyte (INCY): Barclays Raises Price Target to $115, Maintains O - GuruFocus
Does Incyte's Expanding Drug Pipeline Signal an Opportunity Following a 46.8% Price Surge? - Yahoo Finance
Incyte (INCY) Tops Goldman Sachs' Hedge Fund Concentration List - GuruFocus
Officer Tray Files To Sell 169 Of Incyte Corp [INCY] - TradingView
Commit To Purchase Incyte At $87.50, Earn 12.3% Annualized Using Options - Nasdaq
Is Incyte Corporation (ICY) stock among top earnings playsJuly 2025 Momentum & Fast Gain Swing Alerts - newser.com
Incyte to Present at Upcoming December 2025 Investor Conferences - BioSpace
Incyte Corp. Stock Underperforms Wednesday When Compared To Competitors - 富途牛牛
Is Incyte Corporation (ICY) stock considered safe havenJuly 2025 Trade Ideas & AI Enhanced Execution Alerts - newser.com
Incyte to Present at Upcoming Investor Conferences - Yahoo Finance
Why Incyte (INCY) is a Top Value Stock for the Long-Term - Yahoo Finance
Incyte at Jefferies London: Strategic Shift to Diversification - Investing.com
Incyte Expands ‘Moments of Clarity’ With New Stories Spotlighting Chronic Skin Conditions - MyChesCo
Incyte Stock Outlook: Is Wall Street Bullish or Bearish? - MSN
VP Denton Files To Sell 278 Of Incyte Corp [INCY] - TradingView
Is Incyte Corporation building a consolidation baseEarnings Recap Report & Verified Chart Pattern Signals - newser.com
Incyte (INCY) Receives Positive Opinion for Minjuvi in Europe - GuruFocus
Incyte Announces Positive CHMP Opinion for Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma (FL) - BioSpace
Incyte corp EVP Steven Stein sells shares worth $897,866 - MSN
Can Incyte Corporation (ICY) stock attract analyst upgradesEarnings Trend Report & Reliable Entry Point Trade Alerts - newser.com
Forecasting Incyte Corporation price range with options dataJuly 2025 Outlook & Fast Entry High Yield Tips - newser.com
STATE STREET CORP Reduces Stake in Incyte Corp: A Strategic Port - GuruFocus
What risks investors should watch in Incyte Corporation stockTreasury Yields & AI Powered Market Entry Ideas - newser.com
Incyte Corp. stock underperforms Friday when compared to competitors - MarketWatch
Incyte Corp. Stock Underperforms Thursday When Compared To Competitors - 富途牛牛
Key metrics from Incyte Corporation’s quarterly dataJuly 2025 Weekly Recap & Advanced Swing Trade Entry Plans - newser.com
Why Analysts See Incyte’s Story Shifting as Pipeline Progress Drives New Valuation Targets - Yahoo Finance
Incyte Corporation (INCY) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Will Incyte Corporation stock see PE expansionQuarterly Growth Report & Weekly High Return Opportunities - newser.com
Incyte Corp. stock underperforms Thursday when compared to competitors - MarketWatch
Incyte Prepares to Showcase Pipeline Momentum With New mutCALR Data at ASH 2025 - MyChesCo
Incyte (INCY): Exploring Valuation After Recent Share Price Rally and Pipeline Progress - Yahoo Finance
Incyte stock hits 52-week high at 108.81 USD By Investing.com - Investing.com Canada
Incyte stock hits 52-week high at 108.81 USD - Investing.com
Peering Into Incyte Corp's Recent Short Interest - Benzinga
Incyte Posts 20% Revenue Growth, Raises 2025 Outlook on Strong Drug Demand - MSN
Incyte Corp. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Prelude Therapeutics Reshapes Pipeline With Incyte Deal and Strategic Refocus - MyChesCo
The Bull Case For Incyte (INCY) Could Change Following Raised 2025 Guidance and Oncology Program Updates – Learn Why - simplywall.st
Prelude Strikes $910 Million Deal With Incyte for Groundbreaking JAK2 Cancer Therapy - MyChesCo
1.10%
1.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):